Search the Newsreel

Viridian Therapeutics (VRDN) Goldman Sachs 46th Annual Global Healthcare Conference summary

Viridian Therapeutics showcased its progress at the Goldman Sachs 46th Annual Global Healthcare Conference, highlighting positive Phase 3 data for its active and chronic Thyroid Eye Disease (TED) treatments, with BLA filing targeted for the second half of the year. The company emphasized the …

Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today

Viridian Therapeutics (VRDN) stock has dropped 37.8% year-to-date, but despite this decline, valuation checks suggest it remains expensive, trading at a high P/S ratio of 29.7x compared to industry averages. The tailored Fair Ratio further indicates overvaluation, although this can also serve as a …

VRDN6389238 Bond Coupon Profile — Rate & Payments

This article provides key details about the Viridian Therapeutics, Inc. VRDN6389238 bond. It highlights the current coupon rate of 1.75% and indicates that the next interest payment is scheduled for November 16, 2026. The piece also notes that further in-depth coupon data and an …

Virinchi Ltd revises audited annual results for FY26

Virinchi Share Price Target 2026: Rs 20 Analyst Forecast

Virinchi reports FY26 net loss of ₹273.87 crore

Virinchi reports consolidated net loss of Rs 14.61 crore in the March 2026 quarter

Virinchi board to meet on May 28 to consider FY26 results

Virinchi Limited Allots 8.5 Lakh Equity Shares on Warrant Conversion Worth Rs.1.79 Crore

Virinchi Limited Promoter Viswanath Kompella Acquires 20,000 Additional Shares

Vivo Bio Tech Limited Acquires 15.59% Stake in Virinchi Limited Through Convertible Equity Warrants

Lacklustre Performance Is Driving Virinchi Limited's (NSE:VIRINCHI) Low P/S

Viridien: Prévisions et Estimations des Analystes | VIRI